Swissmedic expands on existing multilateral agreement
This article was originally published in SRA
Executive Summary
A meeting between the national drug and device authorities of Switzerland ( Swissmedic), Australia ( Therapeutic Goods Administration), Canada ( Health Canada) and Singapore ( Health Sciences Authority) has served to intensify the existing collaboration among the countries1. The principal focus of a new co-operative agreement signed by the various bodies is on initiatives in the fields of marketing authorisation and market surveillance.